Top Markets
#1 MarsCoin MarsCoin +55.22%
#2 Palladium Network Palladium Network +52.93%
#3 Siren Siren +27.72%
#4 Useless Coin Useless Coin +25.64%
#5 Status Status +20.53%
#6 edgeX edgeX +18.18%
#7 Bedrock Bedrock +17.35%
#8 PondCoin PondCoin +15.89%
#9 Asteroid Shiba Asteroid Shiba +15.47%
#10 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.19%
Coin of the day
MarsCoin MarsCoin
Settings
Language
ENGLISH
Currency
USD
Theme
KemPharm, Inc. KemPharm, Inc.

KemPharm, Inc.

KMPH
Rank in Stocks #18400
KemPharm, Inc. operates as a specialized pharmaceutical firm focused on... KemPharm, Inc. operates as a specialized pharmaceutical firm focused on discovering and advancing proprietary prodrugs to tackle serious medical conditions across the United States. The company employs its innovative Ligand Activated Therapy (LAT) platform to create improved prodrug versions of medications already approved by the FDA, and also to develop prodrugs from existing compounds for potential applications in new disease indications. Its pipeline of investigational prodrugs strategically targets high-need areas such as attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) disorders, including idiopathic hypersomnia (IH). KP1077, KemPharm's leading experimental compound, is a prodrug of d-methylphenidate, known as serdexmethylphnidate, and is currently in Phase II clinical trials for the treatment of IH and narcolepsy. Additionally, the company is advancing KP879, a prodrug candidate designed to treat stimulant use disorder, which is undergoing Phase I clinical evaluation. KemPharm has also obtained FDA approval for AZSTARYS, a new once-daily ADHD treatment for patients aged six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company holds collaboration and license agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Founded in 2006, KemPharm, Inc. is headquartered in Celebration, Florida.
Share Price
$5.81
Last synced: 2023-02-28
Market Cap
$200.14M
Change (1 day)
-0.34%
Change (1 year)
0.00%
Country
US
Trade KemPharm, Inc. (KMPH)

Category

Healthcare
Number of shares outstanding for KemPharm, Inc. (KMPH)
Number of shares outstanding as of September 2026: 0
According to KemPharm, Inc. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of September 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for KemPharm, Inc. (KMPH) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH